Evil:
The Wednesday press release stated they "plan to aggressively pursue development of PRO-140 as a therapy for women with metastatic triple negative breast cancer, assess PRO-140 in metastatic colon cancer, remain committed to concurrently advancing clinical programs in GvHD & HIV" amongst other pronouncements.
It's no secret I'm not a fan of Pourhassan ( or Mulholland who's equally responsible for financing fiasco), however he must be given credit for advancing these trials forward and laying groundwork to expand the pipeline. We're nearly three months out from the GvHD June 20th press release stating "patient enrollment is underway at five clinical sites and the next review of data will occur following enrollment of 10 patients under amended protocol after each patient has been dosed for 30 days" --
I believe we'll see good news regarding the increased dosing protocol soon.
However and sadly as we know, management was convinced this forthcoming/past noteworthy accomplishments would catapult the PPS enticing warrant holders to exercise options and provide long term operating funds in a friendly organic manner. A gross miscalculation, hard, embarrassing and shareholder punishing lesson learned.
It does appear they can raise funds under the current conditions as needed- and if still steadfastly against R/S & up listing we'd require four similar rounds of financing to hold us through November 2019 where we'd have approximately 305 million shares and 170 warrants outstanding.
Until then the pattern will continue- positive news spikes PPS to $.70cts-.80cts and subsequent poor financing brings it back down to the .50cts --
AI
Market Data 
Markets 
